Potency Biomarkers for Mesenchymal Stem Cells
This novel high-capacity assay developed to quantify the clonal heterogeneity in MSC potency is inexpensive and uses readily available antibodies. The potential market for this technology is large because it is applicable to MSC therapies for a variety of diseases and to the preparation of tissue samples with MSCs for drug development.
- Expedites the quantification and enrichment of multipotent progenitors in donor MSC preparations for research and clinical applications.- Enables the consistent and rapid production of highly efficacious MSC therapies from a variety of donors for a broad range of disorders- Useful screening tool in the clinical setting to monitor progenitor content in MSC therapies from different donors - Enables the rapid production of autologous MSC therapies with consistent efficacy among different patients- Improves the efficiency in production of MSC therapies for myocardial infarction and other acute, time-critical conditions
None
美國
